Home > Haematology > EHA 2019 > Benign Haematology > New sickle cell drug voxelotor boosts levels of haemoglobin

New sickle cell drug voxelotor boosts levels of haemoglobin

Presented By
Dr Jo Howard, King’s College London, United Kingdom
Conference
EHA 2019
Trial
Phase 3, HOPE
Results from the randomised, placebo-controlled, phase 3 Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) trial of voxelotor in adults and adolescents with sickle cell disease showed promising effects on anaemia and haemolysis in roughly 60% of patients included [1]. As well as being presented at the EHA meeting, the data were simultaneously published in the New England Journal of Medicine [2]. Dr Jo Howard (King’s College London, United Kingdom) presented new data from the late-stage HOPE trial, which showed that voxelotor, a new treatment for sickle cell disease (SCD), significantly improves anaemia and haemolysis, and provides strong evidence that voxelotor has the potential to be a disease-modifying treatment that could prevent chronic organ damage. SCD is a genetic blood disorder that affects millions worldwide and can cause ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on